Litcius/Paper detail

OA15.03 Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS

Alexander I. Spira, Matthew Krebs, Byoung Chul Cho, Benjamin Besse, Jonathan W. Goldman, Pasi A. Jänne, Chee Khoon Lee, Z. Ma, Aaron S. Mansfield, Anna Minchom, Sai‐Hong Ignatius Ou, Ravi Salgia, Z. Wang, Ge Gao, John P. Curtin, Amy Roshak, Robert W. Schnepp, Meena Thayu, Roland E. Knoblauch, José Trigo

2021Journal of Thoracic Oncology18 citationsDOI

Topics & Concepts

MedicineExonLung cancerEpidermal growth factor receptorOncologyRefractory (planetary science)Targeted therapyInternal medicineChemotherapyCancer researchMutationCancerGeneGeneticsBiologyAstrobiologyLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentColorectal Cancer Treatments and Studies
OA15.03 Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS | Litcius